LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Novartis AG

Cerrado

117.96 0.28

Resumen

Variación precio

24h

Actual

Mínimo

117.25

Máximo

118.42

Métricas clave

By Trading Economics

Ingresos

786M

3.6B

Ventas

62M

14B

P/B

Media del Sector

18.292

51.198

BPA

2.28

Rentabilidad por dividendo

3.42

Margen de beneficios

26.476

Empleados

75,883

EBITDA

643M

5.8B

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 Meses

-4.36% downside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

3.42%

2.40%

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

13B

230B

Apertura anterior

117.68

Cierre anterior

117.96

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

Novartis AG Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

12 may 2025, 09:36 UTC

Principales Movimientos del Mercado

Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

30 abr 2025, 16:35 UTC

Principales Movimientos del Mercado
Adquisiciones, fusiones, absorciones

Regulus Shares Surge on $1.7 Billion Acquisition by Novartis

30 abr 2025, 11:55 UTC

Adquisiciones, fusiones, absorciones

Novartis to Acquire MicroRNA-Technology Specialist Regulus for Up to $1.7 Billion

30 abr 2025, 11:54 UTC

Adquisiciones, fusiones, absorciones

Novartis to Acquire Regulus in $1.7 Billion Deal

29 abr 2025, 07:09 UTC

Ganancias

Novartis Lifts Guidance After Profit, Sales Top Views -- Update

29 abr 2025, 05:36 UTC

Ganancias

Novartis Lifts Guidance After Profit, Sales Top Views

2 jun 2025, 14:17 UTC

Charlas de Mercado

Novartis's Pluvicto Delivers Positive Results in Third Late-Stage Trial -- Market Talk

27 may 2025, 12:04 UTC

Adquisiciones, fusiones, absorciones

Correct: Novartis Will Offer $7.00 in Cash Per Share

27 may 2025, 12:01 UTC

Adquisiciones, fusiones, absorciones

Novartis: Offer Will Expire on June 24

27 may 2025, 12:00 UTC

Adquisiciones, fusiones, absorciones

Novartis Will Offer $0.001 Per Share

27 may 2025, 11:59 UTC

Adquisiciones, fusiones, absorciones

Novartis: Offer Is to Acquire All Outstanding Shares of Regulus Therapeutics's Common Stock

27 may 2025, 11:59 UTC

Adquisiciones, fusiones, absorciones

Novartis: Redwood Merger Sub Inc. Is an Indirect Wholly Owned Subsidiary of Novartis

27 may 2025, 11:58 UTC

Adquisiciones, fusiones, absorciones

Novartis: Redwood Merger Sub Inc. Has Commenced a Tender Offer

27 may 2025, 11:57 UTC

Adquisiciones, fusiones, absorciones

Novartis Announces Commencement of Tender Offer to Buy Regulus Therapeutics

12 may 2025, 22:14 UTC

Principales Noticias

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12 may 2025, 18:45 UTC

Principales Noticias

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

30 abr 2025, 11:40 UTC

Adquisiciones, fusiones, absorciones

Novartis to Acquire MicroRNA-Technology Specialist Regulus for Up to $1.7 Bln

30 abr 2025, 11:39 UTC

Adquisiciones, fusiones, absorciones

Novartis to Acquire Regulus in $1.7B Deal

30 abr 2025, 11:16 UTC

Adquisiciones, fusiones, absorciones

Novartis: Transaction Is Expected to Close in Second Half of 2025

30 abr 2025, 11:15 UTC

Adquisiciones, fusiones, absorciones

Novartis: Regulus Therapeutics Is U.S. Biotech Focused on microRNA Therapeutics

30 abr 2025, 11:14 UTC

Adquisiciones, fusiones, absorciones

Novartis: Transaction Includes USD0.8B Upfront Payment, Potential Additional USD 0.9B Payment

30 abr 2025, 11:13 UTC

Adquisiciones, fusiones, absorciones

Novartis to Buy Regulus Therapeutics

29 abr 2025, 12:34 UTC

Charlas de Mercado
Ganancias

Novartis Solid Result Shifts Investor Focus to 2H -- Market Talk

29 abr 2025, 11:54 UTC

Charlas de Mercado
Ganancias

Correction to Novartis Market Talk

29 abr 2025, 11:47 UTC

Charlas de Mercado
Ganancias

Novartis Guidance Lift Seems Positive Signal for Investors -- Market Talk

29 abr 2025, 10:42 UTC

Charlas de Mercado
Ganancias

Novartis Surprises With Another Beat & Raise -- Market Talk

29 abr 2025, 10:16 UTC

Charlas de Mercado
Ganancias

Novartis's Guidance Lift Reflects Strong Sales -- Market Talk

29 abr 2025, 05:06 UTC

Ganancias

Novartis Had Seen Core Operating Profit to Grow at High Single to Low Double-Digit in 2025 at Constant Currencies

29 abr 2025, 05:06 UTC

Ganancias

Novartis Expects Core Operating Profit to Grow Low Double-Digit in 2025 at Constant Currencies

29 abr 2025, 05:05 UTC

Ganancias

Novartis Had Seen Sales Grow Mid- to High-Single Digit in 2025 at Constant Currencies

Comparación entre iguales

Cambio de precio

Novartis AG previsión

Precio Objetivo

By TipRanks

-4.36% descenso

Estimación a 12 Meses

Media 112.66 USD  -4.36%

Máximo 135.307 USD

Mínimo 88 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Novartis AG Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

6 ratings

2

Comprar

3

Mantener

1

Vender

Puntuación técnica

By Trading Central

N/A / 112.63Soporte y Resistencia

Corto Plazo

Bearish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Strong Bullish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Novartis AG

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.